IMG-007

IMG-007 is ImageneBio's (formerly Inmagene, post-merger with Ikena Oncology) non-depleting anti-OX40 monoclonal antibody, engineered with a silenced Fc (the antibody tail that recruits immune cells) and extended half-life to enable every-12-week (Q12W) dosing [1][7]. It is in a 405-patient Phase 2b dose-finding trial for moderate-to-severe atopic dermatitis (NCT07037901; NCT07-range registration unverified at our model cutoff and should be confirmed on ClinicalTrials.gov) [1]. The pitch: Q12W dosing in a market dominated by Dupixent's every-2-week (Q2W) injections. The reality: IMG-007 is the third anti-OX40 program in atopic dermatitis behind Amgen/Kyowa Kirin's rocatinlimab (whose ROCKET Phase 3 IGNITE study hit co-primary endpoints in March 2025, and whose ASCEND long-term extension hit in September 2025) and Sanofi's amlitelimab (anti-OX40L, Phase 3) [2][3][11][12]. Rocatinlimab's Phase 3 wins de-risk the mechanism but also raise the competitive bar - IMG-007 now needs to beat a Phase 3-validated competitor on dosing interval or durability, not just on placebo-controlled efficacy, to carve share from a $14B+ Dupixent franchise [4].

Novel investigational antibody, never approved anywhere. Currently in Phase 2b for atopic dermatitis (NCT07037901), recruiting against a target of 405 adults [1]. Primary endpoint is mean percent change from baseline in Eczema Area and Severity Index (EASI) at Week 24, with placebo control and multiple dose arms. The specific dosing intervals tested (notably whether Q8W or Q12W arms are included) are not detailed in the public registration text we could access - this is a material information gap because Q12W dosing is the central differentiation claim and the Phase 2a alopecia program already demonstrated Q12W dosing intent in IMG-007's design [13]. A Phase 2a in alopecia areata (NCT06060977, n=29) reported topline results in April 2025: dose-related hair regrowth and improvements in Severity of Alopecia Tool (SALT) scores in the 600 mg cohort that had not plateaued by Week 36 after a 4-week induction, with a well-tolerated safety profile [13]. A healthy-volunteer Phase 1 (NCT05353972, n=44) also wrapped [6]. No public FDA breakthrough therapy, fast track, or orphan designations have been disclosed. Given the Week 24 primary timepoint and current recruiting status, a topline atopic dermatitis readout is unlikely before late 2027 at earliest. Inmagene's de-SPAC merger with Ikena Oncology (a reverse merger via a publicly traded shell - Ikena was a struggling oncology company that became the listed vehicle) was announced December 23, 2024 and closed mid-2025, with the combined entity renamed ImageneBio (NASDAQ: IMA) and ~$175M in combined financing (including a $75M concurrent PIPE) earmarked for IMG-007 development [7]. Cash runway specifics are not broken out in public filings we have verified here; at typical small-biotech burn for a Phase 2b/3 transition, $175M is roughly 2-3 years of runway absent a partnership.

OX40 (gene name TNFRSF4) sits on the surface of recently activated T cells and acts like an accelerator pedal. When the T cell sees its target antigen and gets the first signal, OX40 engagement by its partner OX40L on dendritic cells provides the second signal that says 'survive longer, divide more, become a long-lived memory cell' [8]. In atopic dermatitis, the pathogenic T cells are Th2-skewed - they pump out IL-4, IL-13, and IL-31, which drive the itch, the barrier breakdown, and the eosinophil infiltrate that defines the disease. OX40 and OX40L are upregulated in lesional atopic dermatitis skin compared to non-lesional skin, providing the tissue-level rationale for targeting this axis [9]. Blocking OX40 starves Th2 cells of their costimulatory signal without killing them outright. IMG-007 is engineered as 'non-depleting' - its Fc region (the antibody's tail, which normally recruits immune cells to destroy the bound target) is silenced so it does not trigger antibody-dependent cellular cytotoxicity against OX40-expressing lymphocytes. That contrasts with rocatinlimab, which is depleting [2]. The primary clinical validation of OX40 as a target in atopic dermatitis is rocatinlimab's Phase 2b data (mean EASI reductions of -48% to -61% across rocatinlimab arms versus -15% placebo at Week 16, with benefit persisting months after dosing stopped) and now the positive ROCKET IGNITE Phase 3 readout (March 2025), which confirmed the mechanism in a key-scale population [2][11].

NCT07037901 is described as a Phase 2b randomized, double-blind, placebo-controlled, parallel-group dose-finding study enrolling roughly 405 adults with moderate-to-severe atopic dermatitis [1]. Primary endpoint: mean percent change in EASI from baseline to Week 24. Sponsor is Inmagene LLC (now operating as ImageneBio post-merger). The design is conventional and appropriate - multiple doses against placebo, a 24-week readout long enough to see whether benefit holds and whether the extended half-life translates into a real dosing advantage. Full enrollment of 405 patients in this indication typically takes 12-18 months given the crowded competitive trial environment. Two design questions matter for interpretation: first, whether the trial reports EASI-75 (the proportion of patients achieving ≥75% improvement in EASI) and IGA 0/1 (Investigator's Global Assessment scored 0=clear or 1=almost clear on a 0-4 scale - the FDA's standard cosmetic-clearance endpoint for approval) alongside mean percent change, and second, whether dosing intervals tested include Q8W (every 8 weeks) or Q12W (every 12 weeks) - the only way IMG-007 differentiates from Dupixent's Q2W (every 2 weeks) regimen on convenience. Without head-to-head data against Dupixent (none planned), the placebo-controlled result will be compared cross-trial to rocatinlimab's Phase 2b and Phase 3 IGNITE results and amlitelimab's Phase 2b - a noisy comparison that physicians and payers will discount.

Our model estimates a 10% chance this drug is eventually approved. It starts from a historical base rate of about 32% for Phase 2 drugs in this area, then adjusts based on ten facts about the trial and sponsor. The estimate is helped by larger-than-typical enrollment and an unusually multi-arm design (9 arms), but pulled down by heavier-than-usual blinding and the sponsor's thin or weak approval record. The remaining factors are close to average for this stage, so they leave the final estimate well below the starting point.

Commercial risk is the dominant story. Dupixent (dupilumab, Sanofi/Regeneron) generated roughly $14.5B in 2024 across all indications, with atopic dermatitis the largest contributor, and continues to grow with strong physician familiarity, broad payer coverage, and an expanding label [4]. Lebrikizumab and tralokinumab (IL-13 antibodies) and upadacitinib (oral JAK1 inhibitor) have already failed to dislodge it. IMG-007 needs a clear differentiation story - either a durable post-treatment response that lets patients drug-holiday, or a Q12W dosing interval that genuinely improves on Q2W Dupixent injections. Efficacy risk: anti-OX40 may not match IL-4/IL-13 blockade in raw EASI improvement; Th2 cytokine blockade has set a high bar. Safety risk: chronic costimulation blockade raises theoretical infection and malignancy concerns over years of dosing - particularly relevant because rare humans with germline OX40 loss-of-function present with combined immunodeficiency, which is a theoretical (not observed) ceiling on what sustained pharmacological blockade could approximate at the extreme [9]. Rocatinlimab's emerging Phase 3 safety profile from IGNITE has been manageable so far [11]. Execution risk is real - ImageneBio is a small-cap company post-de-SPAC with ~$175M of disclosed financing, and a Phase 3 anti-OX40 program in atopic dermatitis would likely require a partner [7]. Class risk has decreased materially given rocatinlimab Phase 3 wins, but cross-trial efficacy benchmarking risk has increased - IMG-007 must now clear a validated competitor's bar, not just placebo.

Re-rate from 'wait for the binary' to 'watch the readout against a validated bar.' The original framing - IMG-007 as a used option on rocatinlimab Phase 3 - is obsolete because that Phase 3 (IGNITE) already hit in March 2025 and the long-term extension (ASCEND) hit in September 2025 [11][12]. The OX40 thesis is alive. The remaining question is whether IMG-007 specifically can compete. Signals to watch: (1) when ImageneBio reports interim or topline Phase 2b atopic dermatitis data (likely late 2027 at earliest given Week 24 primary timepoint and current recruiting status), the relevant cross-trial benchmark is rocatinlimab's Phase 2b mean EASI percent reduction of -48% to -61% across active arms at Week 16 (versus -15% placebo) - IMG-007 needs to land in that range or better, ideally at a longer dosing interval [2]; (2) whether the Phase 2b includes Q12W dosing arms and whether they hold efficacy - this is the entire differentiation thesis; (3) any disclosed partnership discussions, since Phase 3 in atopic dermatitis against Dupixent is not a viable solo path for a $175M-financed small-cap [7]. The amlitelimab Phase 3 readouts are also relevant cross-mechanism support [3]. Specific catalyst-date guidance for ROCKET that we can confirm: IGNITE topline March 2025 (hit); ASCEND long-term extension September 2025 (hit); additional ROCKET program publications expected through 2026. Investor takeaway: this is now a competitive-positioning story, not a mechanism-binary story.